Merck & Co., Inc.(MRK)
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest News & Analysis
Merck's Keytruda Approval & Pipeline Progress: An [MRK](/dashboard/companies/MRK) Analysis
Merck's recent FDA approval of Keytruda for head and neck cancer, coupled with advancements in its vaccine and veterinary pipelines, positions the company for continued growth.
Merck's Strategic Pivot: Dengue Vaccine Trial and Regulatory Headwinds
Merck's latest strategic moves, including a new dengue vaccine trial and animal health approval, navigate complex regulatory and competitive landscapes.
Merck & Co. (MRK): Clinical Advances and Regulatory Resilience
Merck & Co. navigates a complex landscape of clinical advancements and regulatory pressures, with its stock reflecting nuanced market sentiment.
Merck's Strategy: Navigating Keytruda Cliff with Pipeline & M&A
Explore Merck's strategic maneuvers, pipeline advancements, and financial health as it navigates the impending Keytruda patent cliff and evolving market dynamics.
Merck (MRK) Earnings Preview: Keytruda, Gardasil, and Legal Challenges
Merck (MRK) approaches Q1 2025 earnings, balancing Keytruda strength with Gardasil China headwinds, legal challenges, and industry dynamics.
Merck (MRK) Stock Analysis: Navigating Lawsuits, Dividends, and Volatility
Analysis of Merck & Co. (MRK) amid lawsuits, tariff risks, and Gardasil uncertainties. Dividend appeal, R&D pipeline, and market sentiment explored.
Merck (MRK) Stock Analysis: Navigating Legal Challenges and Growth
Merck (MRK) faces lawsuits amid portfolio expansion. A $2B deal with Jiangsu Hengrui and EU approval for CAPVAXIVE® highlight growth efforts. Dividend appeal key.
Merck (MRK) Faces Investor Lawsuits: Analyzing Gardasil Allegations
Merck (MRK) faces investor lawsuits over Gardasil sales allegations. This analysis examines the claims, financial impact, and Merck's defense.
Merck (MRK): Securities Lawsuits, Gardasil Sales, and Investor Risks
Merck (MRK) faces securities lawsuits over Gardasil sales disclosures. Analysis of allegations, financials, and analyst outlook for MRK amidst these challenges.
Merck (MRK): Legal Battles, HIV Drug Progress, and Investor Outlook
Analysis of Merck's legal challenges, HIV drug advancements, financial performance, and investor considerations. Stay informed on MRK's market position.
Merck (MRK) Faces Investor Lawsuits: Gardasil Sales Under Scrutiny
Merck (MRK) faces investor lawsuits over Gardasil sales in China amidst Keytruda patent expiration. Dividend yield is attractive, but challenges loom. Stock price: $96.61.
Merck & Co., Inc.: Intraday Update on Legal and Pipeline News
A comprehensive intraday update for Merck & Co., Inc. on March 5, 2025, covering shareholder lawsuits, patent disputes, and pipeline diversification.
Merck (MRK) Faces Investor Lawsuits: Impact on Stock and Outlook
Merck (MRK) faces investor lawsuits amid promising pipeline developments. Analysis covers legal challenges, oncology portfolio, financial stability, and market outlook.
Merck (MRK) Under Scrutiny: Class Action Lawsuits and Investor Concerns
Merck (MRK) faces investor lawsuits over Gardasil sales projections, impacting investor confidence and stock. The lead plaintiff deadline is April 14, 2025.
Merck (MRK) News: Keytruda, Lawsuits, and Future Growth Strategies
Merck & Co. navigates Keytruda's success, lawsuits, and strategic growth amid looming price controls and global expansion efforts. A comprehensive market analysis.
Merck Faces Investor Lawsuits Amid Dividend Stock Rotation
Merck (MRK) faces securities fraud lawsuits amidst a dividend stock rotation. Analysis includes allegations, responses, interest rate impacts, and conference participation.
Merck (MRK) Under Scrutiny: Securities Fraud Lawsuit Impacts Investors
Merck faces multiple securities fraud lawsuits impacting investor sentiment and stock valuation. Detailed analysis and key insights provided.
Merck & Co., Inc.: Industry Impact and Market Trends Analysis
Merck & Co., Inc. faces securities fraud investigations amid analyst optimism, presenting a complex investment landscape. Key legal, financial, and market insights provided.
Merck (MRK) Under Investigation: Impact on Investors
Merck (MRK) faces securities fraud investigations amid Keytruda's success and a Gardasil setback, impacting investor confidence and market strategy.
Merck Faces Investor Lawsuits Amid Gardasil Sales Concerns and Vaccine Case Delay
A series of class action lawsuits and a delayed vaccine trial are challenging Merck, forcing scrutiny of Gardasil sales and future growth.
Merck Navigates Legal and Regulatory Challenges
Merck faces legal, regulatory, and market challenges today amid securities lawsuits and delayed vaccine trials, as our analysis reveals.